Why Covid-19 Vaccines Might Be Big Pharma’s Last Big Chance to Repair Its Reputation

Most Americans don't like or trust pharmaceutical firms, but maybe a needle stick can change their minds

Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.

On Dec. 8, 2020, a 90-year-old woman sat in a high-backed chair at the University Hospital in Coventry, U.K., and entered the history books.

Her name was Margaret Keenan and, on that chilly Tuesday, she became the first person on the planet to receive a vaccination for Covid-19. Asked for a comment from the BBC, Keenan—due to turn 91 the following week—said that the Pfizer-BioNTech vaccine she’d just received was the “best early birthday present.”

In a broader sense, that media-saturated needle prick in Coventry was also a very fine present for Pfizer

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in